New hope for Tough-to-Treat myeloma: experimental drug OPN-6602 enters human testing
Disease control
Recruiting now
This early-phase study tests an experimental drug called OPN-6602, given alone or with a steroid (dexamethasone), in people with multiple myeloma that has returned or stopped responding to at least three prior treatments. The main goals are to check the drug's safety, side effect…
Phase: PHASE1 • Sponsor: Opna Bio LLC • Aim: Disease control
Last updated May 06, 2026 16:03 UTC